BROOKS LABORATORIES LTD.

Brooks Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This restriction will be in effect from July 1, 2026, until 48 hours after the declaration of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The closure aligns with SEBI (Prohibition of Insider Trading) Regulations and the company's internal code of conduct, aimed at preventing insider trading during the period leading up to and immediately following the financial results announcement.

Brooks Laboratories Ltd announced the approval by its Board of Directors for the sale of 51,220 equity shares, representing 16.33% of its holding, in its subsidiary Brooks Steriscience Limited to Steriscience Specialties Private Limited. The transaction, valued at ₹20,760 per share, aggregates to approximately ₹106.33 crore. This partial divestment is part of the company's strategy to monetize its investment and will be used for growth initiatives, including expansion and general corporate purposes. Post-transaction, Brooks Laboratories will retain a 32.67% stake in Brooks Steriscience Limited.

Brooks Laboratories Ltd announced on June 19, 2026, that its Board of Directors has approved the sale of 51,220 equity shares in its subsidiary, Brooks Steriscience Limited, to Steriscience Specialties Private Limited. The sale, for a cash consideration of ₹20,760 per share, aggregates to approximately ₹106.33 crore. This transaction represents a partial monetization of the company's investment, not a complete divestment. Following the sale, Brooks Laboratories will retain 1,02,440 equity shares, representing 32.67% of Brooks Steriscience's paid-up share capital. The proceeds will be used to fund the company's growth strategy, including operational expansion and general corporate purposes.

Brooks Laboratories Ltd has appointed Mr. Prashant Rathi as the Chief Executive Officer (CEO) of the company, effective June 1, 2026. This decision was made based on the recommendation of the Nomination and Remuneration Committee and approved by the Board of Directors on May 29, 2026. Mr. Rathi will hold this position in addition to his current role as Chief Financial Officer (CFO). He has been with the company for over five years and brings 13 years of experience in accounting, finance, and financial management.

Brooks Laboratories Ltd's board meeting on May 29, 2026, approved audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. The auditors expressed an unmodified opinion. The company's plan to diversify its business segments via alteration of the Object Clause of the Memorandum of Association was not approved. Mr. Prashant Rathi was appointed as CEO in addition to his role as CFO.

Brooks Laboratories Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory auditors expressed an unmodified opinion on the results. The company's earlier plan to diversify its business segments has been shelved as the alteration to the Object Clause was not approved. Mr. Prashant Rathi has been appointed as CEO in addition to his role as CFO.

Brooks Laboratories Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window for directors, designated persons, and their relatives has been closed since April 1, 2026, and will reopen 48 hours after the declaration of the audited financial results.

Brooks Laboratories Ltd reports that Brooks Steriscience Limited (BSL), a joint venture/associate, has decided not to pursue the proposed composite scheme of arrangement and amalgamation involving Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited and Onesource Specialty Pharma Limited in its current form. The decision was made by BSL's Board of Directors in the best interest of all stakeholders.

Brooks Laboratories Ltd has responded to a clarification sought regarding price movement. The company has disclosed all material information to the stock exchange, including information that could impact operations or performance, in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. There is no pending Unpublished Price Sensitive Information that could affect the price or volume behavior of the scrip. The company is not aware of the reason for the significant changes in its share price, attributing it to market-driven factors. The management is not connected with the changes in share prices. Brooks Laboratories Ltd reaffirms its commitment to adhere to compliances required under the Listing Regulations and other applicable laws.

Brooks Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives, effective from 1st April 2026 until 48 hours after the declaration of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2026. This move is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) (Second Amendment) Regulation, 2019, and the company's Code of Conduct for prevention of Insider Trading. The details of the Board Meeting and the reopening of the Trading Window will be intimated in due course.